NO126298B - - Google Patents
Download PDFInfo
- Publication number
- NO126298B NO126298B NO00168375A NO16837567A NO126298B NO 126298 B NO126298 B NO 126298B NO 00168375 A NO00168375 A NO 00168375A NO 16837567 A NO16837567 A NO 16837567A NO 126298 B NO126298 B NO 126298B
- Authority
- NO
- Norway
- Prior art keywords
- oxytetracycline
- solution
- solutions
- magnesium
- polyvinylpyrrolidone
- Prior art date
Links
- 239000000243 solution Substances 0.000 claims description 66
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 32
- 239000004100 Oxytetracycline Substances 0.000 claims description 31
- 229960000625 oxytetracycline Drugs 0.000 claims description 31
- 235000019366 oxytetracycline Nutrition 0.000 claims description 31
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 24
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 24
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 23
- 239000000395 magnesium oxide Substances 0.000 claims description 11
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 11
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000002681 magnesium compounds Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 16
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 11
- VYGBQXDNOUHIBZ-UHFFFAOYSA-L sodium formaldehyde sulphoxylate Chemical compound [Na+].[Na+].O=C.[O-]S[O-] VYGBQXDNOUHIBZ-UHFFFAOYSA-L 0.000 description 11
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000005521 carbonamide group Chemical group 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003924 oxytetracycline dihydrate Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL6607516A NL6607516A (enExample) | 1966-05-31 | 1966-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO126298B true NO126298B (enExample) | 1973-01-22 |
Family
ID=19796753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO00168375A NO126298B (enExample) | 1966-05-31 | 1967-05-30 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3557280A (enExample) |
| JP (1) | JPS5010373B1 (enExample) |
| AT (1) | AT272522B (enExample) |
| BE (1) | BE699091A (enExample) |
| CH (1) | CH490087A (enExample) |
| CS (1) | CS151454B2 (enExample) |
| DE (1) | DE1617576C3 (enExample) |
| DK (1) | DK117587B (enExample) |
| ES (1) | ES340956A1 (enExample) |
| FI (1) | FI43622B (enExample) |
| FR (1) | FR5953M (enExample) |
| GB (1) | GB1131007A (enExample) |
| GR (1) | GR33861B (enExample) |
| IL (1) | IL28009A (enExample) |
| IT (1) | IT1140250B (enExample) |
| LU (1) | LU53788A1 (enExample) |
| MY (1) | MY7100015A (enExample) |
| NL (1) | NL6607516A (enExample) |
| NO (1) | NO126298B (enExample) |
| SE (1) | SE354417B (enExample) |
| SU (1) | SU510986A3 (enExample) |
| YU (1) | YU31326B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5418330B2 (enExample) * | 1973-03-16 | 1979-07-06 | ||
| US3966905A (en) * | 1973-05-29 | 1976-06-29 | Barnes-Hind Pharmaceuticals, Inc. | Stabilized catechol amine solutions |
| US3929989A (en) * | 1974-06-14 | 1975-12-30 | Wendt Lab Inc | Stable suspension of calcium-magnesium oxytetracycline for intrauterine administration in treatment of bovine metritis |
| GB1538903A (en) * | 1975-04-11 | 1979-01-24 | Nelson Res & Dev | Carrier for a topically applied physiologically active agent or cosmetic agent |
| US4018889A (en) * | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| DE2602363C2 (de) * | 1976-01-22 | 1984-04-12 | Bayer Ag, 5090 Leverkusen | Wäßrige, injizierbare Niclofolan- Formulierungen |
| GB1592053A (en) * | 1976-12-16 | 1981-07-01 | Norbrook Lab Ltd | Oxytetracycline compositions |
| US4213963A (en) * | 1978-12-14 | 1980-07-22 | Janssen Pharmaceutica N.V. | Fluspirilene-containing compositions |
| US4259331A (en) * | 1979-04-16 | 1981-03-31 | Pfizer Inc. | Oxytetracycline compositions |
| US4386083A (en) * | 1980-04-10 | 1983-05-31 | Walter Hacke | Injectable oxytetracycline compositions |
| US4399127A (en) * | 1980-04-10 | 1983-08-16 | Diamond Shamrock Corporation | Injectable oxytetracycline compositions |
| IE74244B1 (en) * | 1985-10-01 | 1997-07-16 | Bimeda Res Dev Ltd | A process for preparing an antibiotic composition |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| US6756365B2 (en) * | 1991-11-06 | 2004-06-29 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| EP0626171A1 (de) * | 1993-05-26 | 1994-11-30 | Winfried Dörnhöfer | Injektionslösung für die intravenöse oder intramuskuläre Verabreichung an Tiere |
| US6383515B2 (en) | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
| CZ301835B6 (cs) | 1999-09-14 | 2010-07-07 | Trustees Of Tufts College | Zpusob prípravy 7-, 9- nebo 13- substituované tetracyklinové slouceniny, reaktivní tetracyklinový chemický komplex a tetracyklinová sloucenina substituovaná v poloze 7 nebo 9 |
| US8106225B2 (en) * | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| US6500812B2 (en) | 1999-09-14 | 2002-12-31 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| US6849615B2 (en) | 1999-09-14 | 2005-02-01 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| US6833365B2 (en) | 2000-01-24 | 2004-12-21 | Trustees Of Tufts College | Tetracycline compounds for treatment of Cryptosporidium parvum related disorders |
| ATE365710T1 (de) * | 2000-03-31 | 2007-07-15 | Tufts College | 7- und 9-carbamat, harnstoff, thioharnstoff, thiocarbamat und heteroaryl-amino substituierte tetracyclinverbindungen |
| AU2001259701A1 (en) * | 2000-05-15 | 2001-11-26 | Paratek Pharmaceuticals, Inc | 7-substituted fused ring tetracycline compounds |
| US20040224927A1 (en) | 2000-06-16 | 2004-11-11 | Trustees Of Tufts College | 7-N-substituted phenyl tetracycline compounds |
| US20020132798A1 (en) * | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| WO2001098236A2 (en) * | 2000-06-16 | 2001-12-27 | Trustees Of Tufts College | 7-phenyl-substituted tetracycline compounds |
| BR0112265A (pt) | 2000-07-07 | 2003-06-24 | Tufts College | Compostos de tetraciclina substituìda, e de sanciclina 7-substituìda, método para tratar um estado responsivo à tetraciclina em um indivìduo, e, composição farmacêutica |
| US7094806B2 (en) * | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| ATE504562T1 (de) | 2000-07-07 | 2011-04-15 | Tufts College | 7-, 8- und 9-substitutierte tetracyclinverbindungen |
| US20050143353A1 (en) * | 2000-07-07 | 2005-06-30 | Paratek Pharmaceuticals, Inc. | 13-Substituted methacycline compounds |
| AU2001271616A1 (en) | 2000-07-07 | 2002-01-21 | Paratek Pharmaceuticals, Inc | 13-substituted methacycline compounds |
| CZ2003344A3 (cs) | 2000-07-07 | 2003-05-14 | Trustees Of Tufts College | 9-Substituované minocyklinové sloučeniny |
| WO2002072532A1 (en) | 2001-03-13 | 2002-09-19 | Paratek Pharmaceuticals, Inc. | 7, 9-substituted tetracycline compounds |
| AU2002250331A1 (en) * | 2001-03-13 | 2002-09-24 | Paratek Pharmaceuticals, Inc. | 7-pyrollyl tetracycline compounds and methods of use thereof |
| US6841546B2 (en) | 2001-03-14 | 2005-01-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds as antifungal agents |
| EP1381372A2 (en) | 2001-03-14 | 2004-01-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds as synergistic antifungal agents |
| EP1399414B1 (en) | 2001-04-24 | 2010-01-13 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| US8088820B2 (en) * | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| EP2311797A1 (en) * | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| JP2005526754A (ja) | 2002-03-08 | 2005-09-08 | パラテック ファーマシューティカルズ インコーポレイテッド | アミノメチル置換されたテトラサイクリン化合物 |
| EP1503981A4 (en) | 2002-03-21 | 2007-08-15 | Paratek Pharm Innc | SUBSTITUTED TETRACYCLINE COMPOUNDS |
| WO2004006850A2 (en) | 2002-07-12 | 2004-01-22 | Paratek Pharmaceuticals, Inc | 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| WO2004038001A2 (en) | 2002-10-24 | 2004-05-06 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| WO2004071490A1 (en) * | 2003-02-12 | 2004-08-26 | R & P Korea Co., Ltd. | Solvent system of hardly soluble drug with improved elution rate |
| US20060287283A1 (en) * | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| WO2005009943A2 (en) | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4738333B2 (ja) | 2003-07-09 | 2011-08-03 | パラテック ファーマシューティカルズ インコーポレイテッド | ９−アミノメチルテトラサイクリン化合物のプロドラッグ |
| EP2332904A3 (en) * | 2004-01-15 | 2012-04-11 | Paratek Pharmaceuticals, Inc. | Derivatives of tetracycline compounds |
| TWI261038B (en) * | 2004-08-11 | 2006-09-01 | Bo-Cheng Chen | Bicycle gear-shifting handgrip |
| JP2008518025A (ja) * | 2004-10-25 | 2008-05-29 | パラテック ファーマシューティカルズ インコーポレイテッド | ４−アミノテトラサイクリンおよびその使用の方法 |
| WO2006047756A2 (en) | 2004-10-25 | 2006-05-04 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| AU2006210406C1 (en) | 2005-02-04 | 2013-03-07 | Paratek Pharmaceuticals, Inc. | 11a, 12-derivatives of tetracycline compounds |
| DE102005012595A1 (de) * | 2005-03-18 | 2006-09-21 | Lanxess Deutschland Gmbh | Herstellung von Tri(chlorpropyl)phosphat |
| CA2616224A1 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| US20080269334A1 (en) * | 2005-09-19 | 2008-10-30 | Albemarle Corporation | Highly Concentrated Pourable Aqueous Solutions Of Potassium Ibuprofen, Their Preparation And Their Use |
| EP1991236A2 (en) | 2006-01-24 | 2008-11-19 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
| EP2007713A2 (en) * | 2006-04-17 | 2008-12-31 | Teva Pharmaceutical Industries Ltd | Isolation of tetracycline derivatives |
| US8198470B2 (en) * | 2006-04-24 | 2012-06-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form II of tigecycline and processes for preparation thereof |
| PT2016045E (pt) * | 2006-04-24 | 2015-02-05 | Teva Pharma | Forma cristalina de tigeciclina e processos para a sua preparação |
| WO2007133797A2 (en) * | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| WO2008045507A2 (en) | 2006-10-11 | 2008-04-17 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of bacillus anthracis infections |
| IL270446B2 (en) * | 2006-12-21 | 2023-10-01 | Paratek Pharm Innc | A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition |
| PL2120963T3 (pl) | 2006-12-21 | 2019-05-31 | Paratek Pharm Innc | Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry |
| EP2144614A1 (en) * | 2007-04-12 | 2010-01-20 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| EP2144870A2 (en) * | 2007-04-27 | 2010-01-20 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| WO2009009042A1 (en) | 2007-07-06 | 2009-01-15 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| MX2010009693A (es) * | 2008-03-05 | 2010-12-20 | Paratek Pharm Innc | Compuestos de monociclina y metodos de uso de la misma. |
| PT2271348T (pt) | 2008-03-28 | 2018-04-16 | Paratek Pharm Innc | Formulação de comprimido oral de composto de tetraciclina |
| JP2011517697A (ja) * | 2008-04-14 | 2011-06-16 | パラテック ファーマシューティカルズ インコーポレイテッド | 置換テトラサイクリン化合物 |
| TWI585071B (zh) | 2008-05-19 | 2017-06-01 | 派洛泰克藥物股份有限公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| EP2309988B1 (en) * | 2008-07-21 | 2015-11-25 | SI Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| US9629809B2 (en) | 2008-07-21 | 2017-04-25 | Si Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| EP2341771A4 (en) * | 2008-09-19 | 2012-08-15 | Paratek Pharm Innc | TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED THERAPEUTIC METHODS |
| JP2012523438A (ja) | 2009-04-10 | 2012-10-04 | タフツ メディカル センター インコーポレイテッド | メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化 |
| LT2707003T (lt) | 2011-05-12 | 2019-10-10 | Paratek Pharmaceuticals, Inc. | Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai |
| SG11201903846TA (en) | 2016-11-01 | 2019-05-30 | Paratek Pharm Innc | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) |
| CA3070663A1 (en) | 2017-07-21 | 2019-01-24 | Almirall, Llc | Treatment of non-inflammatory lesions |
-
1966
- 1966-05-31 NL NL6607516A patent/NL6607516A/xx unknown
- 1966-11-08 FR FR82837A patent/FR5953M/fr not_active Expired
-
1967
- 1967-05-16 GB GB22620/67A patent/GB1131007A/en not_active Expired
- 1967-05-18 IL IL28009A patent/IL28009A/en unknown
- 1967-05-18 SE SE06961/67A patent/SE354417B/xx unknown
- 1967-05-22 GR GR670133861A patent/GR33861B/el unknown
- 1967-05-24 ES ES340956A patent/ES340956A1/es not_active Expired
- 1967-05-25 SU SU1158241A patent/SU510986A3/ru active
- 1967-05-26 US US641483A patent/US3557280A/en not_active Expired - Lifetime
- 1967-05-26 DE DE1617576A patent/DE1617576C3/de not_active Expired
- 1967-05-26 BE BE699091D patent/BE699091A/xx not_active IP Right Cessation
- 1967-05-30 AT AT502267A patent/AT272522B/de active
- 1967-05-30 IT IT37118/67A patent/IT1140250B/it active
- 1967-05-30 NO NO00168375A patent/NO126298B/no unknown
- 1967-05-30 FI FI1517/67A patent/FI43622B/fi active
- 1967-05-30 YU YU1086/67A patent/YU31326B/xx unknown
- 1967-05-30 DK DK282167AA patent/DK117587B/da unknown
- 1967-05-31 CH CH766867A patent/CH490087A/de not_active IP Right Cessation
- 1967-05-31 LU LU53788A patent/LU53788A1/xx unknown
- 1967-05-31 JP JP42034292A patent/JPS5010373B1/ja active Pending
- 1967-05-31 CS CS3970A patent/CS151454B2/cs unknown
-
1971
- 1971-12-30 MY MY15/71A patent/MY7100015A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1617576C3 (de) | 1980-12-11 |
| FI43622B (enExample) | 1971-02-01 |
| DE1617576A1 (de) | 1972-04-27 |
| AT272522B (de) | 1969-07-10 |
| IL28009A (en) | 1970-08-19 |
| YU31326B (en) | 1973-04-30 |
| SU510986A3 (ru) | 1976-04-15 |
| US3557280A (en) | 1971-01-19 |
| JPS5010373B1 (enExample) | 1975-04-21 |
| ES340956A1 (es) | 1968-06-16 |
| NL6607516A (enExample) | 1967-12-01 |
| GB1131007A (en) | 1968-10-16 |
| CH490087A (de) | 1970-05-15 |
| SE354417B (enExample) | 1973-03-12 |
| GR33861B (el) | 1968-02-09 |
| IT1140250B (it) | 1986-09-24 |
| DK117587B (da) | 1970-05-11 |
| FR5953M (enExample) | 1968-04-16 |
| DE1617576B2 (de) | 1980-04-10 |
| BE699091A (enExample) | 1967-11-27 |
| LU53788A1 (enExample) | 1967-07-31 |
| CS151454B2 (enExample) | 1973-10-19 |
| MY7100015A (en) | 1971-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3557280A (en) | Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation | |
| RU2260429C2 (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| US20120142779A1 (en) | Stable injectable compositions | |
| IT8448182A1 (it) | Composizioni farmaceutiche contenenti ranitidina e procedimento per prepararle | |
| UA80961C2 (en) | Process for obtaining of freeze-dried pantoprazole preparation, lyophilized pantoprazole preparation, injection solution based on pantoprazole and injection kit | |
| US7638556B2 (en) | Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof | |
| US3957972A (en) | Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation | |
| US5124152A (en) | Parenteral formulation of metolazone | |
| KR101924786B1 (ko) | 이부프로펜의 주사용 약제학적 조성물 | |
| PT90356B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo solucoes aquosas de pentamidina | |
| JP2019502720A (ja) | バンコマイシンの製剤 | |
| JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
| JPH10508598A (ja) | トロンビン阻害剤を含有する貯蔵安定な輸液用水溶液 | |
| NO168375B (no) | Fremgangsmaate for delignifisering av celluloseholdig materiale | |
| EP1166773B1 (en) | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | |
| JPS61126014A (ja) | 経鼻投与用水性液剤 | |
| US3969524A (en) | Stable amoxicillin dosage form | |
| KR0156929B1 (ko) | 안정화된수용성펜타미딘염수용액 | |
| CN100417416C (zh) | 含新鱼腥草素钠和Solutol HS15的药物组合物 | |
| US4301160A (en) | Ready for use, injectable, aqueous solutions of alkali metal salts of canrenoic acid and furosemide and process for their preparation | |
| KR0137647B1 (ko) | 이보파민의 수용성 산 부가 염을 포함하는 안과용 약학 조성물 | |
| KR920006911B1 (ko) | 안정한 피록시캄 주사액 조성물 및 그의 제조방법 | |
| KR100606621B1 (ko) | 에카베트 나트륨 수성 용액 제제 | |
| GB1592053A (en) | Oxytetracycline compositions | |
| US4742082A (en) | Solution of luprostiol and 1,2,-propanediol and methods of preparation and use |